摘要
目的对阿尔茨海默病的治疗方法进行分析探讨。方法将该院2016年1月-2018年6月收治的96例阿尔茨海默病患者随机分为两组,对照组48例患者采用丙戊酸钠缓释片治疗,观察组48例患者采用丙戊酸钠缓释片联合喹硫平治疗,对比两组治疗效果。结果观察组治疗有效率为91.67%,明显高于对照组的79.17%,差异有统计学意义(χ^2=17.291,P<0.05)。观察组治疗后Behave-AD、BPRS及MMSE评分为(6.55±0.71)分、(20.96±3.28)分、(21.39±2.55)分,对照组分别为(10.49±1.25)分、(16.74±2.11)分及(32.66±3.58)分,组间比较差异有统计学意义(t=6.903、12.788、5.202,P<0.05)。观察组治疗后VEGF、NO、IL-1及TNF-α水平为(536.22±107.81)pg/mL、(46.88±5.91)μmol/L、(0.42±0.06)μg/L、(52.34±4.0)pg/mL,对照组为(490.70±91.33)pg/mL、(39.08±3.82)μmol/L、(0.54±0.18)μg/L、(59.12±3.39)pg/mL,组间比较差异有统计学意义(t=6.993、13.291、6.281、16.884,P<0.05)。两组不良反应发生率差异无统计学意义(χ^2=0.091,P>0.05)。结论对阿尔茨海默病采用丙戊酸钠缓释片联合喹硫平治疗,可有效改善患者精神行为,提高患者智力,提高患者的健康与生活质量,值得临床应用、推广。
Objective To analyze the treatment of Alzheimer's disease.Methods 96 patients with Alzheimer's disease admitted to our hospital from January 2016 to June 2018 were randomly divided into two groups.The control group of 48 patients were treated with sodium valproate sustained-release tablets,and the observation group was treated with 48 patients.Sodium valproate sustained-release tablets combined with quetiapine were used to compare the therapeutic ef-fects of the two groups.Results The effective rate of the observation group was 91.67%,which was significantly higher than that of the control group 79.17%,the difference was statistically significant(χ^2=17.291,P<0.05).Behave-AD,BPRS and MMSE scores in the observation group were(6.55±0.71)points,(20.96±3.28)points,(21.39±2.55)points,and the control group were(10.49±1.25)points and(16.74±2.11)points,and(32.66±3.58)points.There were significant dif-ferences between the groups(t=6.903,12.788,5.202,P<0.05).The levels of VEGF,NO,IL-1 and TNF-αin the obser-vation group were(536.22±107.81)pg/mL,(46.88±5.91)μmol/L,(0.42±0.06)μg/L,(52.34±4.0)pg/mL,the control group was(490.70±91.33)pg/mL,(39.08±3.82)μmol/L,(0.54±0.18)μg/L,(59.12±3.39)pg/mL,and there were statistical sig-nificant differences between groups(t=6.993,13.291,6.281,16.884,P<0.05).There was no statistical significant differ-ence in the incidence of adverse reactions between the two groups(χ^2=0.091,P>0.05).Conclusion The treatment of Alzheimer's disease with sodium valproate sustained-release tablets combined with quetiapine can effectively improve the mental behavior of patients,improve their intelligence and improve their health and quality of life.It is worthy of clinical application.
作者
谢燕荣
XIE Yan-rong(Department of Neurology,Caoxian Hospital,Heze,Shandong Province,274400 China)
出处
《系统医学》
2019年第18期65-67,共3页
Systems Medicine
关键词
阿尔茨海默病
丙戊酸钠缓释片
喹硫平
Alzheimer's disease
Sodium valproate sustained-release tablets
Quetiapine
